Signaling Pathways
A research team is investigating novel therapeutic targets for osteoporosis treatment. They are studying the Wnt signaling pathway and its role in bone formation. A new anti-sclerostin antibody (romosozumab) has been approved for treatment of postmenopausal osteoporosis, demonstrating the clinical relevance of this pathway. Regarding Wnt signaling in bone biology:
Mark each as TRUE or FALSE
The canonical Wnt pathway is a critical regulator of bone formation; Wnt ligands bind to Frizzled re...
Sclerostin (produced by osteocytes, encoded by SOST gene) is a key inhibitor of the Wnt pathway; it ...
Wnt signaling inhibits osteoblast differentiation; sclerostin activates the Wnt pathway; high sclero...
Romosozumab is a humanized anti-sclerostin monoclonal antibody approved for osteoporosis treatment; ...
Other Wnt antagonists include DKK1 (Dickkopf-1) and sFRP (secreted Frizzled-related proteins); these...
Answer the questions to see explanations
Click T (True) or F (False) for each option